Activation of complement by pathogenic and nonpathogenic Entamoeba histolytica.
Open Access
- 15 March 1986
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 136 (6) , 2265-2270
- https://doi.org/10.4049/jimmunol.136.6.2265
Abstract
Previous studies had demonstrated that strains of Entamoeba histolytica isolated from patients with colitis or amebic liver abscess were resistant to complement-mediated killing, whereas strains from asymptomatic patients were readily lysed by non-immune serum. Both serum-sensitive and serum-resistant strains of E. histolytica depleted complement rapidly as assessed by CH50, C3, and C7, and C5-9 hemolytic activities. Activation of the alternative pathway was important in lysis of nonpathogenic strains, as demonstrated by lysis by NHS (60.9 +/- 15.6%) and NHS + 5 mM EGTA (59.3 +/- 4.5%) as well as by C4-deficient guinea pig serum (72.8 +/- 7.1%) and C2-deficient human serum (64.4 +/- 11.1%), but not by NHS + 5 mM EDTA. Classical pathway activation also occurs as both pathogenic and nonpathogenic strains deplete greater than 98% of C4 activity, although it is not necessary for lysis. Pathogenic strains are not lysed by either the classical or the alternative pathway. These results suggest that pathogenic strains of E. histolytica activate complement but are able to evade an important host defense, complement-mediated lysis.This publication has 14 references indexed in Scilit:
- BIOCHEMICAL HOMOGENEITY OF ENTAMOEBA HISTOLYTICA ISOLATES, ESPECIALLY THOSE FROM LIVER ABSCESSThe Lancet, 1982
- Attachment and ingestion of bacteria by trophozoites of Entamoeba histolyticaInfection and Immunity, 1982
- Studies on the mechanism of bacterial resistance to complement-mediated killing. II. C8 and C9 release C5b67 from the surface of salmonella minnesota S218 because the terminal complex does not insert into the bacterial outer membraneThe Journal of Experimental Medicine, 1982
- Studies on the mechanism of bacterial resistance to complement-mediated killing. I. Terminal complement components are deposited and released from salmonella minnesota S218 without causing bacterial deathThe Journal of Experimental Medicine, 1982
- Activation of the alternative complement pathway by Trichomonas vaginalisInfection and Immunity, 1981
- Enzymatic treatment transforms trypomastigotes of Trypanosoma cruzi into activators of alternative complement pathway and potentiates their uptake by macrophages.Proceedings of the National Academy of Sciences, 1981
- Newly transformed schistosomula spontaneously lose surface antigens and C3 acceptor sites during culture.The Journal of Immunology, 1980
- Experimental AmebiasisThe American Journal of Tropical Medicine and Hygiene, 1978
- ACTIVATION OF ALTERNATIVE PATHWAY OF COMPLEMENT BY ENTAMOEBA-HISTOLYTICA1978
- ENHANCEMENT OF THE HEMOLYTIC ACTIVITY OF THE SECOND COMPONENT OF HUMAN COMPLEMENT BY OXIDATIONThe Journal of Experimental Medicine, 1967